Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

Franse aandelen Terug naar discussie overzicht

Biophytis ontploft, Integragen en Theradiag next!

395 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 20 »» | Laatste | Omlaag ↓
  2. i know it 21 april 2020 10:23

    • i know it

      Lid sinds: 22 dec 2015

      Laatste bezoek: 28 jul 2024

    • Aanbevelingen

      Ontvangen: 14

      Gegeven: 1

    •    Aantal posts: 230

    About BIOPHYTIS 
    Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuro muscular diseases.Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development in H2 2020.Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus) for which the company has filed a clinical trial application with the French Regulatory Authority (ANSM).The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.

    5 Posts

    Aanta

  3. i know it 21 april 2020 10:37

    • i know it

      Lid sinds: 22 dec 2015

      Laatste bezoek: 28 jul 2024

    • Aanbevelingen

      Ontvangen: 14

      Gegeven: 1

    •    Aantal posts: 230

    Correction - Biophytis launches a Public Offering of
    Share Subscription Warrants (BSA) with an Irreducible Priority
    Subscription Period for Existing Shareholders
    Paris (France), Cambridge (Etats-Unis), April 21 , 2020, 8:00 a.m. CEST – BIOPHYTIS (Euronext Growth
    Paris: ALBPS), today issued a correction of the press release issued on April 7, 2020, in order to
    consolidate important information relating to the offer to the public of Share Subscription Warrants
    (BSA) with an irreducible priority period for shareholders. This information was included until today in
    the Synthetic Information Document (DIS) posted on the Biophytis website on April 7, 2020. However,
    under this transaction, the Company was not subject to the publication of a DIS.

    Below is the corrected press release:
    Paris, (France), Cambridge (Massachusetts, United States), Biophytis SA (Euronext Growth Paris: ALBPS
    a clinical-stage biotechnology company specialized in the development of drug candidates for treatment
    of aged related diseases, especially neuromuscular diseases, announced on April 7, 2020 the launch of
    a public offering of 7,445,123 Share Subscription Warrants (BSA), which could be increased to 7,475,708
    BSA, by way of a public offering with an irreducible priority subscription period for existing shareholders,
    as well as an extension clause.
    Offering price
    The subscription price will be €0.06 per BSA for a total amount of €446,707.38 and €448,542.48 if the
    extension clause is exercised.
    BSA Offering
    The proposed issuance of the 7,445,123 BSA, to be subscribed in cash, will be carried out with
    shareholders’ preferential subscription rights removed. The Offer will include (i) a priority period for
    shareholders on an irreducible basis only, with 3 BSA for every 16 shares held as of April 8, 2020
    (operation settled at this date) (rounded to the higher unit if the number of shares is not a multiple of
    16) and (ii) an extension clause to increase the issue to 7,475,708 BSA.
    Shareholders registered as of April 8, 2020 (operation settled at this date) will benefit from a non-
    negotiable and non-transferable subscription priority period, from April 9, 2020 to April 21, 2020
    included at 12:00 p.m. (Paris time). As a result, all shares purchased on 7
    th and 8th April 2020 will not
    benefit from the priority period.
    As part of the priority period, the Company's shareholders will be able to subscribe on an irreducible
    basis to the extent of their shares in the Company's capital pursuant to the terms set out above. There
    are no plans to allow subscriptions on a reducible basis during the priority period.
    Unsubscribed BSAs will then be offered first to the Company's employees and executive officers within
    the limits of their requests. The Priority Period relates to the initial issuance amount, excluding the
  4. i know it 21 april 2020 10:39

    • i know it

      Lid sinds: 22 dec 2015

      Laatste bezoek: 28 jul 2024

    • Aanbevelingen

      Ontvangen: 14

      Gegeven: 1

    •    Aantal posts: 230

    Waarom denken mensen dat het naar 0,30 cent gaat ??? Lees dan eens goed ! Voor bestaande aandeelhouders die er al langer inzitten hebben een voordeel. Maar op zeker boven de 2 euro eind van de week
  8. RW1963 21 april 2020 12:21

    • RW1963

      Lid sinds: 16 apr 2015

      Laatste bezoek: 14 jul 2024

    • Aanbevelingen

      Ontvangen: 1324

      Gegeven: 9933

    •    Aantal posts: 6.301

    quote:

    i know it schreef op 21 april 2020 10:39:

    Waarom denken mensen dat het naar 0,30 cent gaat ??? Lees dan eens goed ! Voor bestaande aandeelhouders die er al langer inzitten hebben een voordeel. Maar op zeker boven de 2 euro eind van de week
    JAMMER!
    Je bent al weer flink gezakt t.o.v. een eerdere voorspelling.

    i know it 17 april 2020 17:19

    Oh ja tot ver over de 3 euro...
  14. [verwijderd] 21 april 2020 12:50

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    forumwatcher schreef op 21 april 2020 12:46:

    Mijn eerste post mocht er dan ook wel ééntje zijn met goed nieuws :)
    Haha thanks Forumwatcher!
    tot nu toe ziet het er goed uit, hoop dat je zelf ook profiteert ;)
395 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 20 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 6.998
AB InBev 2 5.480
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.167
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.476
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.632
Aedifica 3 900
Aegon 3.258 322.634
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.884
Agfa-Gevaert 14 2.047
Ahold 3.538 74.290
Air France - KLM 1.025 34.976
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.032
Alfen 16 24.273
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 404
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.834 242.660
AMG 971 133.025
AMS 3 73
Amsterdam Commodities 305 6.685
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 481
Antonov 22.632 153.605
Aperam 92 14.886
Apollo Alternative Assets 1 17
Apple 5 379
Arcadis 252 8.731
Arcelor Mittal 2.033 320.477
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.282
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.075
ASML 1.766 105.724
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 466
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.601
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.388